{
    "name": "diazoxide",
    "comment": "Rx",
    "other_names": [
        "Proglycem"
    ],
    "classes": [
        "Glucose-Elevating Agents"
    ],
    "source": "https://reference.medscape.com/drug/proglycem-diazoxide-342311",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Excretion in milk unknown; not recommended"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excretion in milk unknown; not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to diazoxide, thiazides, or sulfonamide derivatives"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in coronary or cerebral insufficiency, DM, extravasation, heart failure (may increase fluid retention), cardiovascular insufficiency, gout, hypotension, hypokalemia, liver disease, renal dysfunction",
                "Pregnancy",
                "Compensatory HTN (aortic coarctation, arteriovenous shunt)",
                "Ineffective in pheochromocytoma",
                "Nonketotic hyperosmolar coma may occur during treatment; transient cataracts reported",
                "May displace bilirubin from albumin; use caution in newborns with hyperbilirubinemia",
                "The antidiuretic property of diazoxide may lead to significant fluid retention, which in patients with compromised cardiac reserve, may precipitate congestive heart failure; the fluid retention will respond to conventional therapy with diuretics",
                "Concomitantly administered thiazides may potentiate the hyperglycemic and hyperuricemic actions of diazoxide",
                "Ketoacidosis and nonketotic hyperosmolar coma reported in patients treated with recommended doses usually during intercurrent illness; prompt recognition and treatment essential and prolonged surveillance following the acute episode necessary because of long drug half-life of approximately 30 hours; occurrence of these serious events may be reduced by careful education of patients regarding monitoring urine for sugar and ketones and for prompt reporting of abnormal findings and unusual symptoms to healthcare provider",
                "Effects of diazoxide on the hematopoietic system and the level of serum uric acid kept in mind; the latter should be considered particularly in patients with hyperuricemia or a history of gout",
                "Antihypertensive effect of other drugs may be enhanced by diazoxide; should keep this in mind when administering it concomitantly with antihypertensive agents",
                "Because of protein binding, administration of diazoxide with coumarin or its derivatives may require reduction in dosage of anticoagulants"
            ],
            "specific": [
                {
                    "type": "Pulmonary hypertension in newborns and infants",
                    "description": [
                        "July 16, 2015: FDA warns clinicians to watch for signs of pulmonary hypertension in infants treated for hypoglycemia with diazoxide and discontinue the drug if symptoms appear",
                        "There have been 11 cases identified since the drug was approved (1973) and once diazoxide was discontinued, the symptoms resolved",
                        "Signs of respiratory distress include flaring nostrils, grunting, unusual chest movements, rapid breathing, difficulty feeding, or a bluish tint to the lips or skin",
                        "Monitoring is especially important for infants who have other risk factors for pulmonary hypertension (eg, meconium aspiration syndrome, respiratory distress syndrome, transient tachypnea of the newborn, pneumonia, sepsis, congenital diaphragmatic hernia, and congenital heart disease)"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, diazoxide.\nEither increases effects of the other by anti-hypertensive channel blocking. Use Caution/Monitor. Monitor blood pressure and adjust dose accordingly."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "diazoxide increases effects of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Diazoxide may enhance the hypotensive effect of antihypertensive agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "diazoxide, captopril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide increases toxicity of diazoxide by unspecified interaction mechanism. Use Caution/Monitor. May enhance hyperglycemic effects of diazoxide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "diazoxide decreases effects of insulin degludec by pharmacodynamic antagonism. Use Caution/Monitor. Diazoxide increases blood glucose by inhibiting pancreatic insulin release and stimulating catecholamines release."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "diazoxide decreases effects of insulin degludec/insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Diazoxide increases blood glucose by inhibiting pancreatic insulin release and stimulating catecholamines release."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "diazoxide decreases effects of insulin inhaled by pharmacodynamic antagonism. Use Caution/Monitor. Diazoxide increases blood glucose by inhibiting pancreatic insulin release and stimulating catecholamines release."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "diazoxide decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tesamorelin",
            "description": {
                "common": "tesamorelin will decrease the level or effect of diazoxide by  altering metabolism. Modify Therapy/Monitor Closely. Monitor glucose levels"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "diazoxide, bendroflumethiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "diazoxide, chlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "diazoxide, chlorthalidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "diazoxide, cyclopenthiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "diazoxide decreases levels of ethotoin by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "diazoxide decreases levels of fosphenytoin by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydralazine",
            "description": {
                "common": "diazoxide, hydralazine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "diazoxide, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "diazoxide, indapamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "diazoxide, methyclothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "diazoxide, metolazone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "diazoxide decreases levels of phenytoin by increasing metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Angina",
            "percent": null
        },
        {
            "name": "Cardiac arrest",
            "percent": null
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Polyneuritis",
            "percent": null
        },
        {
            "name": "CHF",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Palpitation",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Loss of taste",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Diabetic ketoacidosis",
            "percent": null
        },
        {
            "name": "Hirsutism",
            "percent": null
        },
        {
            "name": "Scalp hair loss",
            "percent": null
        },
        {
            "name": "Hyperglycemia",
            "percent": null
        },
        {
            "name": "Sodium and fluid retention",
            "percent": null
        },
        {
            "name": "Pulmonary hypertension in neonates and young infants",
            "percent": null
        }
    ]
}